Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors

Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors

Purpose FDG-positive neuroendocrine tumors (NETs) have a poorer prognosis and exhibit shorter response duration to peptide receptor radionuclide therapy (PRRT). The aim of this prospective phase II study was to evaluate the efficacy and toxicity of PRRT with 177 Lu-DOTATATE associated with metronomi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of nuclear medicine and molecular imaging 2021-09, Vol.48 (10), p.3260-3267
Hauptverfasser: Nicolini, Silvia, Bodei, Lisa, Bongiovanni, Alberto, Sansovini, Maddalena, Grassi, Ilaria, Ibrahim, Toni, Monti, Manuela, Caroli, Paola, Sarnelli, Anna, Diano, Danila, Di Iorio, Valentina, Grana, Chiara Maria, Cittanti, Corrado, Pieri, Federica, Severi, Stefano, Paganelli, Giovanni
Format: Artikel
Sprache:eng
Schlagworte:
Adverse events
Asthenia
Cardiology
Criteria
Diarrhea
Disease control
Evaluation
Imaging
Lutetium isotopes
Medical prognosis
Medicine
Medicine & Public Health
Neuroendocrine tumors
Nuclear Medicine
Oncology
Oncology – General
Oral administration
Original Article
Orthopedics
Pancreas
Pancreatic cancer
Patients
Radiation therapy
Radioisotopes
Radiology
Receptors
Solid tumors
Somatostatin
Terminology
Toxicity
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose FDG-positive neuroendocrine tumors (NETs) have a poorer prognosis and exhibit shorter response duration to peptide receptor radionuclide therapy (PRRT). The aim of this prospective phase II study was to evaluate the efficacy and toxicity of PRRT with 177 Lu-DOTATATE associated with metronomic capecitabine as a radiosensitizer agent in patients with advanced progressive FDG-positive gastro-entero-pancreatic (GEP) NETs. Patients and methods Patients with advanced somatostatin receptor- and FDG-positive G1-G3 GEP-NETs (Ki67 
ISSN:1619-7070
1619-7089
DOI:10.1007/s00259-021-05236-z